Βιογραφικό

Καθηγήτρια Νευρολογίας Παν/μίου Marburg, Γερμανία
Υπεύθυνη τμήματος Πάρκινσον και Κινητικών Διαταραχών Νοσοκομείου "ΥΓΕΙΑ"
Εξειδικευμένη στη Νόσο Πάρκινσον & άλλες Κινητικές Διαταραχές, UCL, Αγγλία.

►

Εκπαίδευση & Ακαδημαϊκοί Τίτλοι

2017 - σήμερα Καθηγήτρια Νευρολογίας, Παν/μίου Marburg, Γερμανία
2013-2017 Επίκουρη καθηγήτρια Νευρολογίας, Παν/μίου Marburg, Γερμανία
10/2010-02/2013 Eξειδίκευση στη νόσο Πάρκινσον και Κινητικές Διαταραχές (UCL, Sobell Dept. of Motor Neurosciences and Movement Disorders, Queen Square, London, UK)
01/2005 – 09/2009 PhD, Διδακτορική διατριβή, Tίτλος “Coenzyme Q10 in progressive supranuclear palsy: a randomized, double-blind, placebo-controlled study” (Philipps University, Marburg, Germany, «άριστα με διάκριση», summa cum laude)
01/2005-10/2010 Ειδικότητα Νευρολογίας: Philipps-University, Marburg, Γερμανία
2005-2010 Ειδικά εξωτερικά ιατρεία για νόσο Πάρκινσον και Κινητικές Διαταραχές
2005-2010 Ειδικά εξωτερικά ιατρεία για άτυπα παρκινσονικά σύνδρομα
2009-2010 Ειδικά εξωτερικά ιατρεία για ενδομυϊκές ενέσεις συγκεκριμένης τοξίνης (http://www.hygeia.gr σε δυστονίες, σπαστικότητα και υπεριδρωσία με ηλεκτρομυογραφικό έλεγχο (πιστοποίηση από την γερμανική εταιρεία ΒοΝΤ)
2007-2009 Μονάδα εντατικής θεραπείας για νευρολογικές νόσους (εκπαίδευση σε επείγουσα ιατρική, διασωληνώσεις, τοποθέτηση κεντρικών γραμμών)
2009-2010 Εκπαίδευση στην ηλεκτροφυσιολογία, ΕΜΓ, ΕΝΓ, προκλητά δυναμικά, ΕΕΓ
2001-2002 Erasmus exchange programme: Πανεπιστήμιο Freiburg, Γερμανία
1996-2002 MD, Πτυχίο Ιατρικής: Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Τμήμα Ιατρικής

ΕΚΠΑΙΔΕΥΤΙΚΗ ΠΕΙΡΑ

Διδασκαλία σε προπτυχιακούς και μεταπτυχιακούς φοιτητές στο Παν/μο Marburg από το 2005 εώς σήμερα
Διδασκαλία σε προπτυχιακούς φοιτητές και ειδικευόμενους στην Β’ Παν/κη Νευρολογική κλινική, Αττικό Νοσοκομείο απο το 2013
Ομιλήτριασε teaching courses του Intenational Movement Disorders Society

►

Διδακτορική Διατριβή

►

Μέλος Εταιριών, Συντακτικής Επιτροπής Περιοδικών

►

Επαγγελματική Προϋπηρεσία

►

Κλινικό & Ερευνητικό Ενδιαφέρον

►

Διακρίσεις & Βραβεία

►

Ομιλίες σε διεθνή συνέδρια (selected)

Atypical Parkinson Syndromes: Practical Therapy. 6th German Parkinson Congress, 2009, Marburg, Germany
Effects of coenzyme Q10 in progressive supranuclear palsy. 23. Greek neurology congress, May 2009,Thessaloniki, Greece
Differential Diagnosis of atypical parkinsonian conditions: British-Turkish Meeting, Queen Square, April 2012
Progressive supranuclear palsy: Treatment. Teaching Course, International Movement Disorders Congress,Dublin, Ireland, 2012
PSP diagnostics. 1st German PSP meeting, Munich, Germany, 2012
The spectrum of cranio-cervical dystonias,International Movement Disorders Congress, Sydney, Australia, 2013
Atypical parkinsonism : Summer school for Movement Disorders, MDS, London, July 2013
The differential diagnosis of vascular parkinsonism with Parkinson’s disease and atypical parkinsonism, International Congress of Vascular Dementia, Athens, 2013
PSP treatment: 18th International Movement Disorders Society Congress, Stockholm, June, 2014
Other hereditary parkinsonian syndromes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
Genetic PSP-, CBD-, MSA- look alikes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
PSP-look alikes: 50 Years of progressive supranuclear palsy; MDS, Munich, Germany, 9-10th October 2014
Update on PSP: Annual Parkinson Meeting; Ancona, Italy, 16-17th October 2014
The non-motor syndrome of dystonia: International Congress on Non-motor dysfunction in Parkinson's disease and related disorders (NMDPD), Nice, France, 4-7th December 2014
Movement Disorders in the Media. 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015
Invited expert in Video Challenge, 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015
Update on atypical parkinsonism, Deutsche Gesselschaft für Neurologie (DGN) Kongress, Düsseldorf, October, 2015
Interventions in PSP: World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
Unusual Movement Disorders, Video Session. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
PSP subtypes and phenotypes. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
Atypical Parkinsonism, Parkinson’s congress, Marburg, Germany, 3-5 March 2016
Spasticity-parkinsonism syndromes, Movement Disorders Scholl, Ravello, Italy, 14-16 April, 2016
New classification of dystonia, Greek Movement Disorders School, Thessaloniki, Greece, April 2016
Atypical parkinsonism, MDS Movement Disorders Teaching Course, Kosice, Slovakia, 13-15 May 2016
Update on atypical parkinsonism, 2^nd European Academy of Neurology Congress, Copenhagen, Denmark, 29-31 May 2016
Atypical parkinsonism, Academy of Neurosciences Movement Disorders School, Ioannina, Greece, 3-4 June 2016
Movement Disorders Grand rounds, 20^th international congress of Parkinson's disease and Movement Disorders, 19-23 June 2016
New therapies in parkinsonism, International meeting of the Cyprus Neurological Society Nicosia, Cyprus 12-14 November 2016
Essential and other tremor syndromes, International meeting of the Cyprus Neurological Society, Nicosia, Cyprus 12-14 November 2016
Is imaging very useful in the diagnosis of parkinsonism? 11^th World congress on controversies in Neurology, 25-29 March 2017
The role of gastrointestinal system in the pathogenesis of PD. 11^th World congress on controversies in Neurology, 25-29 March 2017
Is essential tremor a single entity? 11^th World congress on controversies in Neurology, 25-29 March 2017
‘Freezing of gait in parkisnon’s disease’, Movement Disorders school, Corfu, Greece, May 2017
Atypical Parkinsonism, Movement Disorders school, Corfu, Greece, May 2017
Distinguishing PSP, MSA and CBS, 2^nd EAN congress, Amsterdam, June, 2017
Atypical parkinsonism, Greek Neurology congress, Kalamata, June 2017
Pitfalls in MSA Diagnosis: 20 years a-synuclein, Vravrona, Athens, September 2017
The role of SPECT in the differential diagnosis of parkinsonism, Athens, December 2017

►

Βιβλία

►

Δημοσιεύσεις

ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ
Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, et al. Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121. [Epub ahead of print]
Papagiannakis N, Koros C, Stamelou M, et al. Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease.Neurosci Lett. 2017 Nov 10. [Epub ahead of print]
Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep;32(9):1264-1310.
Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, Espay AJ, Fung V, Garcia-Ruiz PJ, Gershanik O, Jankovic J, Kaji R, Kotschet K, Marras C, Miyasaki JM, Morgante F, Munchau A, Pal PK, Rodriguez Oroz MC, Rodríguez-Violante M, Schöls L, Stamelou M, et al. Treatable inherited rare movement disorders. Mov Disord. 2017 Sep 1. [Epub ahead of print]
Darling A, Tello C, Martí MJ, Garrido C, Aguilera-Albesa S, Tomás Vila M, Gastón I, Madruga M, González Gutiérrez L, Ramos Lizana J, Pujol M, Gavilán Iglesias T, Tustin K, Lin JP, Zorzi G, Nardocci N, Martorell L, Lorenzo Sanz G, Gutiérrez F, García PJ, Vela L, Hernández Lahoz C, Ortigoza Escobar JD, Martí Sánchez L, Moreira F, Coelho M, Correia Guedes L, Castro Caldas A, Ferreira J, Pires P, Costa C, Rego P, Magalhães M, Stamelou M, et al. Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. Mov Disord. 2017 Nov;32(11):1620-1630.
Bhatia KP, Stamelou M. Nonmotor Features in Atypical Parkinsonism. Int Rev Neurobiol. 2017;134:1285-1301.
Mandemakers W, Quadri M, Stamelou M, Bonifati V. TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease? Mov Disord. 2017 Aug;32(8):1159-1162.
Bhatia KP, Chaudhuri KR, Stamelou M. Preface. Int Rev Neurobiol. 2017;132:xv.
Schreglmann SR, Bhatia KP, Stamelou M. Advances in the Clinical Differential Diagnosis of Parkinson's Disease. Int Rev Neurobiol. 2017;132:79-127.
Erro R, Stamelou M. The Motor Syndrome of Parkinson's Disease. Int Rev Neurobiol. 2017;132:25-32. doi: 10.1016/bs.irn.2017.01.004.
Carecchio M, Mencacci NE, Iodice A, Pons R, Panteghini C, Zorzi G, Zibordi F, Bonakis A, Dinopoulos A, Jankovic J, Stefanis L, Bhatia KP, Monti V, R'Bibo L, Veneziano L, Garavaglia B, Fusco C, Wood N, Stamelou M, Nardocci N. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug;41:37-43.
Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017 Jul;32(7):995-1005.
Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord. 2017 Jul;32(7):955-971.
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017 Jun;32(6):853-864.
Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ; AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.Mov Disord. 2017 Jun;32(6):842-852.
Hirschbichler ST, Erro R, Ganos C, Stamelou M, Batla A, Balint B, Bhatia KP.
"Atypical" atypical parkinsonism: Critical appraisal of a cohort. Parkinsonism Relat Disord. 2017 Apr;37:36-42.
Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, et al. Manual MRI morphometry in Parkinsonian syndromes. Mov Disord. 2017 May;32(5):778-782.
Obeso JA, Jon Stoessl A, Stamelou M. Editors' Note: The 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Jan;32(1):1.
Boura E, Stamelou M, et al. Is increased spinal nociception another hallmark for Parkinson's disease? J Neurol. 2017 Mar;264(3):570-575.
Bougea A, Koros C, Stamelou M, et al. Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism Relat Disord. 2017 Feb;35:82-87.
Batla A, Stamelou M. Primary familial brain calcification in the IBGC2 kindred: All linkage roads lead to SLC20A2. Mov Disord. 2016 Dec;31(12):1765-1766.
Huppertz HJ, Möller L, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Respondek G, Stamelou M, et al. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord. 2016 Oct;31(10):1506-1517.
Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-León J, Bhatia KP, Deuschl G, Forjaz MJ, Hallett M, Louis ED, Lyons KE, Mestre TA, Raethjen J, Stamelou M, Tan EK, Testa CM, Elble RJ. Transducer-based evaluation of tremor. Mov Disord. 2016 Sep;31(9):1327-36.
Stamelou M, Bhatia KP. Atypical parkinsonism - new advances. Curr Opin Neurol. 2016 Aug;29(4):480-5.
Stamelou M, Höglinger G. A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs. 2016 Jul;30(7):629-36.
Papadimitriou D, Antonelou R, Miligkos M, Maniati M, Papagiannakis N, Bostantjopoulou S, Leonardos A, Koros C, Simitsi A, Papageorgiou SG, Kapaki E, Alcalay RN, Papadimitriou A, Athanassiadou A, Stamelou M, Stefanis L. Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. Mov Disord. 2016 Aug;31(8):1226-30.
Stamelou M, Schöpe J, Wagenpfeil S, et al. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord. 2016 May;31(5):742-7.
Ganos C, Crowe B, Stamelou M, et al. The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism Relat Disord. 2016 Mar;24:20-7.
Mylius V, Pee S, Pape H, Teepker M, Stamelou M, Eggert K, Lefaucheur JP, Oertel WH, Möller JC. Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage Eur J Pain. 2016 Sep;20(8):1223-8.
Valadas A, Contarino MF, Albanese A, Bhatia KP, Falup-Pecurariu C, Forsgren L, Friedman A, Giladi N, Hutchinson M, Kostic VS, Krauss JK, Lokkegaard A, Marti MJ, Milanov I, Pirtosek Z, Relja M, Skorvanek M, Stamelou M, et al. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. Eur J Neurol. 2016 Apr;23(4):772-9.
Batla A, Pareés I, Edwards MJ, Stamelou M, Bhatia KP, Panicker JN. Lower urinary tract dysfunction in patients with functional movement disorders. J Neurol Sci. 2016 Feb 15;361:192-4.
Stamelou M. Late-onset cerebellar ataxia: Do not forget Friedreich's. Mov Disord. 2016 Jan;31(1):7-8.
Papagiannakis N, Xilouri M, Koros C, Stamelou M, Antonelou R, Maniati M, Papadimitriou D, Moraitou M, Michelakakis H, Stefanis L. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. Mov Disord. 2015 Nov;30(13):1830-4
The clinical and genetic heterogeneity of paroxysmal dyskinesias.Gardiner AR, Jaffer F, Dale RC, Labrum R, Erro R, Meyer E, Xiromerisiou G, Stamelou M, Walker M, Kullmann D, Warner T, Jarman P, Hanna M, Kurian MA, Bhatia KP, Houlden H.Brain. 2015 Dec;138(Pt 12):3567-80.
From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link.Respondek G, Höglinger GU, Stamelou M.Mov Disord. 2015 Nov 14.
Interventions in progressive supranuclear palsy. Koros C, Stamelou M.Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S93-5.
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.Nalls
MA, McLean CY, Rick J, et al ; Parkinson's Disease Biomarkers Program and
Parkinson's Progression Marker Initiative investigators.Lancet Neurol. 2015 Oct;14(10):1002-9.
The role of cerebellum in patients with late onset cervical/segmental dystonia?-Evidence from the clinic.Batla A, Sánchez MC, Erro R, Ganos C, Stamelou M, Balint B, Brugger F, Antelmi E, Bhatia KP.Parkinsonism Relat Disord. 2015 Sep 5. pii: S1353-8020(15)00388-0.
Multiple system atrophy-mimicking conditions: Diagnostic challenges.Kim HJ, Stamelou M, Jeon B.Parkinsonism Relat Disord. 2015 Sep 5. pii: S1353-8020(15)00378-8.
The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.Stamelou M, Diehl-Schmid J, Hapfelmeier A, Kontaxopoulou D, Stefanis L, Oertel WH, Bhatia KP, Papageorgiou SG, Höglinger GU.Parkinsonism Relat Disord. 2015 Aug 11. pii: S1353-8020(15)00338-7. doi: 10.1016/
Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. Manohar SG, Chong TT, Apps MA, Batla A, Stamelou M, Jarman PR, Bhatia KP, Husain M.Curr Biol. 2015 Jun 29;25(13):1707-16.
ADCY5 mutations are another cause of benign hereditary chorea. Mencacci NE, Erro R, Wiethoff S, Hersheson J, Ryten M, Balint B, Ganos C, Stamelou M, Quinn N, Houlden H, Wood NW, Bhatia KP. Neurology. 2015 Jul 7;85(1):80-8.
What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies.Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP. J Neurol Neurosurg Psychiatry. 2015 May 19. [Epub ahead of print]
Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study.Stamelou M, Pilatus U, Reuss A, Respondek G, Knake S, Oertel WH, Höglinger GU.Parkinsonism Relat Disord. 2015 Mar 12.
Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia.Charlesworth G, Angelova PR, Bartolomé-Robledo F, Ryten M, Trabzuni D, Stamelou M, Abramov AY, Bhatia KP, Wood NW.Am J Hum Genet. 2015 Apr 2;96(4):657-65. doi: 10.1016/j.ajhg.2015.02.007. Epub 2015 Mar 19.
H-ABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations? Erro R, Hersheson J, Ganos C, Mencacci NE, Stamelou M, et al. .Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26129
Atypical Parkinsonism: Diagnosis and Treatment. Stamelou M, Bhatia KP.Neurol Clin. 2015 Feb;33(1):39-56. doi: 1016/j.ncl.2014.09.012. Review.
The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Respondek G*, Stamelou
M,* et al; for the Movement Disorder Society-endorsed PSP Study Group.Mov Disord. 2014 Nov 5. doi: 10.1002/mds.26054. *equal contribution
Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study.Batla A, Erro R, Stamelou M, et al.Mov Disord. 2014 Oct 28. doi: 10.1002/mds.26018. [Epub ahead of print]
The entity of parkinsonism and associated lipomatosis.Stamelou M, Sheerin UM, Wood N, Bhatia KP. Neurology. 2014 Oct 1
Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes.Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, Bhatia KP, Schott JM, Coles AJ, Kullmann DM, Vincent A.J Neurol Neurosurg Psychiatry. 2014 Sep 22
All in the blink of an eye: new insight into cerebellar and brainstem function in DYT1 and DYT6 dystonia.Sadnicka A, Teo JT, Kojovic M, Pareés I, Saifee TA, Kassavetis P, Schwingenschuh P, Katschnig-Winter P, Stamelou M, Mencacci NE, Rothwell JC, Edwards MJ, Bhatia KP. Eur J Neurol. 2014 Jul 18.
Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou
M, et al; International Parkinson’s Disease Genomics Consortium and UCL-exomes consortium.Brain. 2014 Sep;137(Pt 9):2480-92.
The expanding universe of disorders of the basal ganglia.Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ.Lancet. 2014 Aug 9;384(9942):523-31.
Facial tremor in dystonia.Erro R, Stamelou M, Saifee TA, Ganos C, Antelmi E, Balint B, Cordivari C, Bhatia KP.Parkinsonism Relat Disord. 2014 Aug;20(8):924-5. doi: 10.1016/j.parkreldis.2014.04.029.
Commentary.Stamelou M.Mov Disord. 2014 Mar;29(3):310. doi: 10.1002/mds.25848. No abstract available.
Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty.Macerollo A, Perry R, Stamelou M, Batla A, Mazumder AA, Adams ME, Bhatia KP.Eur J Neurol.2014 Feb;21(2):e16-7.
ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia.Sheerin UM, Schneider SA, Carr L, Deuschl G, Hopfner F, Stamelou M,Wood NW, Bhatia KP.Neurology. 2014 Mar 25;82(12):1065-7.
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators.Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824.
Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T; TAUROS MRI Investigators.Mov Disord. 2014 Apr;29(4):479-87. doi: 10.1002/mds.25815.
The phenotypic spectrum of DYT24 due to ANO3 mutations.Stamelou M, Charlesworth G, Cordivari C, Schneider SA, Kägi G, Sheerin UM, Rubio-Agusti I, Batla A, Houlden H, Wood NW, Bhatia KP. Mov Disord. 2014 Jun;29(7):928-34. doi: 10.1002/mds.25802.
Genome wide association study in cervical dystonia demonstrates possible association with sodium leak channel. Mok KY, Schneider SA, Trabzuni D, Stamelou M, Edwards M, Kasperaviciute D, Pickering-Brown S, Silverdale M, Hardy J, Bhatia KP.Mov Disord. 2013 Nov 13. doi: 10.1002/mds.25732.
Psychogenic paroxysmal movement disorders - Clinical features and diagnostic clues.Ganos C, Aguirregomozcorta M, Batla A, Stamelou M, Schwingenschuh P, Münchau A, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Sep 19.
Ataxia telangiectasia presenting as dopa-responsive cervical dystonia.Charlesworth G, Mohire MD, Schneider SA, Stamelou M, Wood NW, Bhatia KP.Neurology. 2013 Sep 24;81(13):1148-51.
Atypical parkinsonism: an update.Stamelou M, Hoeglinger GU.Curr Opin Neurol. 2013 Aug;26(4):401-5.
MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation.Krismer F, Duerr S, Minnerop M, Klockgether T, Stamelou M, Eggert KM, Oertel WH, Schrag A, Poewe W, Wenning GK.Nervenarzt. 2013 Jun;84(6):709-14.
Markedly asymmetric presentation in multiple system atrophy.Batla A, Stamelou M, Mensikova K, Kaiserova M, Tuckova L, Kanovsky P, Quinn N, Bhatia KP.Parkinsonism Relat Disord. 2013 Oct;19(10):901-5.
Dystonic opisthotonus: A "red flag" for neurodegeneration with brain iron accumulation syndromes?Stamelou M, Lai SC, Aggarwal A, Schneider SA, Houlden H, Yeh TH, Batla A, Lu CS, Bhatt M, Bhatia KP.Mov Disord. 2013 Sep;28(10):1325-9.
"Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide.Stamelou M, Quinn NP, Bhatia KP.Mov Disord. 2013 Aug;28(9):1184-99.
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study.Stamelou M, Christodoulou C, Stefanis L.Mov Disord. 2013 May;28(5):689.
Familial psychogenic movement disorders.Stamelou M, Cossu G, Edwards MJ, Murgia D, Pareés I, Melis M, Bhatia KP.Mov Disord. 2013 Aug;28(9):1295-8. doi: 10.1002/mds.25463.
Commentary for "Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease".Stamelou M. Mov Disord. 2013 Mar;28(3):293-4.
Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort.Rubio-Agusti I, Pareés I, Kojovic M, Stamelou M, Saifee TA, Charlesworth G, Sheerin UM, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Jun;19(6):634-8.
Progressive ataxia and palatal tremor associated with dense pontine calcification: A unique case.Stamelou M, Adams M, Davagnanam I, Batla A, Sheerin U, Talbot K, Bhatia KP. Mov Disord. 2013 Jul;28(8):1155-7.
Functional movement disorders are not uncommon in the elderly.Batla A, Stamelou M, Edwards MJ, Pareés I, Saifee TA, Fox Z, Bhatia KP.Mov Disord. 2013 Apr;28(4):540-3.
Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.Batla A, Stamelou M, Mencacci N, Schapira AH, Bhatia KP.Mov Disord. 2013 Jul;28(8):1159-60.
Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease.Marx S, Respondek G, Stamelou M, Dowiasch S, Stoll J, Bremmer F, Oertel WH, Höglinger GU, Einhäuser W.Front Behav Neurosci. 2012;6:88.
Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.Charlesworth G, Plagnol V, Holmström KM, Bras J, Sheerin UM, Preza E, Rubio-Agusti I, Ryten M, Schneider SA, Stamelou M, Trabzuni D, Abramov AY, Bhatia KP, Wood NW.Am J Hum Genet. 2012 Dec 7;91(6):1041-50.
Patients with rest-tremor and scans with ipsilateral dopaminergic deficit.Aguirregomozcorta M*, Stamelou M,* Antonini A, Schwingenschuh P, Prvulovich L, Edwards MJ, Dickson JC, Bhatia KP.J Neurol. 2013 Apr;260(4):1132-5. *equal contribution
Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation.Sheerin UM, Stamelou M, Charlesworth G, Shiner T, Spacey S, Valente EM, Wood NW, Bhatia KP.J Neurol. 2013 Feb;260(2):656-60.
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine.Gardiner AR, Bhatia KP, Stamelou M, Dale RC, Kurian MA, Schneider SA, Wali GM, Counihan T, Schapira AH, Spacey SD, Valente EM, Silveira-Moriyama L, Teive HA, Raskin S, Sander JW, Lees A, Warner T, Kullmann DM, Wood NW, Hanna M, Houlden H.Neurology. 2012 Nov 20;79(21):2115-21.
The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician.Martino D, Stamelou M, Bhatia KP.J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):650-6.
Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder.Stamelou M, Tuschl K, Chong WK, Burroughs AK, Mills PB, Bhatia KP, Clayton PT.Mov Disord. 2012 Sep 1;27(10):1317-22.
THAP1 mutations and dystonia phenotypes: genotype phenotype correlations.Xiromerisiou G, Houlden H, Scarmeas N, Stamelou M, Kara E, Hardy J, Lees AJ, Korlipara P, Limousin P, Paudel R, Hadjigeorgiou GM, Bhatia KP.Mov Disord. 2012 Sep 1;27(10):1290-4.
Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency.Stamelou M, Mencacci NE, Cordivari C, Batla A, Wood NW, Houlden H, Hardy J, Bhatia KP.Neurology. 2012 Jul 31;79(5):435-41.
A new treatable genetic disorder of manganese metabolism causing dystonia-parkinsonism and cirrhosis: the "new" Wilson's disease?Stamelou M, Bhatia KP.Mov Disord. 2012 Jul;27(8):962.
Late onset rest-tremor in DYT1 dystonia.Stamelou M, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Jan;19(1):136-7.
The distinct movement disorder in anti-NMDA receptor encephalitis may be related to Status Dissociatus: a hypothesis. Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bhatia KP.Mov Disord. 2012 Sep 15;27(11):1360-3.
Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases.Stamelou M, Alonso-Canovas A, Bhatia KP.Mov Disord. 2012 May;27(6):696-702.
Psychogenic palatal tremor may be underrecognized: reappraisal of a large series of cases.Stamelou M, Saifee TA, Edwards MJ, Bhatia KP.Mov Disord. 2012 Aug;27(9):1164-8.
Treatment of focal dystonia.Batla A, Stamelou M, Bhatia KP.Curr Treat Options Neurol. 2012 Jun;14(3):213-29.
Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test.Unger MM, Möller JC, Mankel K, Schmittinger K, Eggert KM, Stamelou M, Stiasny-Kolster K, Bohne K, Bodden M, Mayer G, Oertel WH, Tebbe JJ.Mov Disord. 2011 Dec;26(14):2559-63.
Clinical pain and experimental pain sensitivity in progressive supranuclear palsy.Stamelou M, Dohmann H, Brebermann J, Boura E, Oertel WH, Höglinger G, Möller JC, Mylius V.Parkinsonism Relat Disord. 2012 Jun;18(5):606-8.
Movement disorders on YouTube--caveat spectator.Stamelou M, Edwards MJ, Espay AJ, Fung VS, Hallett M, Lang AE, Tijssen MA, Bhatia KP.N Engl J Med. 2011 Sep 22;365(12):1160-1.
The non-motor syndrome of primary dystonia: clinical and pathophysiological implications.Stamelou M, Edwards MJ, Hallett M, Bhatia KP.Brain. 2012 Jun;135(Pt 6):1668-81.
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, et al .Nat Genet. 2011 Jun 19;43(7):699-705.
Ability to cycle despite severe freezing of gait in atypical parkinsonism in Fahr's syndrome.Stamelou M, Kojovic M, Edwards MJ, Bhatia KP.Mov Disord. 2011 Sep;26(11):2141-2.
Health-related quality of life in multiple system atrophy and progressive supranuclear palsy.Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R.Neurodegener Dis. 2011;8(6):438-46.
Characteristic constant groaning in late stage progressive supranuclear palsy: a case report.Stamelou M, Rubio-Agusti I, Quinn N, Bhatia K.Parkinsonism Relat Disord. 2011 Aug;17(7):575-6.
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B.Mov Disord. 2011 Jun;26(7):1243-50.
Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE.J Neurol. 2011 Oct;258(10):1827-34.
Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes.Stamelou M, Christ H, Reuss A, Oertel W, Höglinger G.Mov Disord. 2011 Apr;26(5):901-5.
Targeting the orexin system: a new approach for treating insomnia.Arias-Carrión O, Stamelou M.CNS Neurol Disord Drug Targets. 2010 Dec;9(6):667.
Magnetic resonance imaging in progressive supranuclear palsy.Stamelou M, Knake S, Oertel WH, Höglinger GU.J Neurol. 2011 Apr;258(4):549-58.
Dopaminergic reward system: a short integrative review.Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, Menéndez-González M, Pöppel E.Int Arch Med. 2010 Oct 6;3:24.
Rational therapeutic approaches to progressive supranuclear palsy.Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU.Brain. 2010 Jun;133(Pt 6):1578-90.
In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.Knake S, Belke M, Menzler K, Pilatus U, Eggert KM, Oertel WH, Stamelou M,* Höglinger GU*.Mov Disord. 2010 Jul 15;25(9):1232-8. *equal contribution
Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.Stamelou M, Matusch A, Elmenhorst D, Hurlemann R, Eggert KM, Zilles K, Oertel WH, Höglinger GU, Bauer A.Mov Disord. 2009 Jun 15;24(8):1170-5.
In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy.Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Knake S, Ruberg M, Schade-Brittinger C, Oertel WH, Höglinger GU.J Cereb Blood Flow Metab. 2009 Apr;29(4):861-70.
Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment.Hattingen E, Lanfermann H, Menon S, Neumann-Haefelin T, de Rochement RD,Stamelou M, Höglinger GU, Magerkurth J, Pilatus U.MAGMA. 2009 Feb;22(1):43-52.
[Atypical Parkinson syndromes].Strzelczyk A, Möller JC, Stamelou M, Matusch A, Oertel WH.Nervenarzt. 2008 Oct;79(10):1203-20
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P.Clin Neuropharmacol. 2008 May-Jun;31(3):151-66.
Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, Krisp A, Menke T, Schade-Brittinger C, Oertel WH, Höglinger GU.Mov Disord. 2008 May 15;23(7):942-9.